{"url_path":"/sec/rna/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2093101/0001193125-26-224238-index.html","accession_number":"0001193125-26-224238","cik":"0002093101","ticker":"RNA","issuer_name":"Atrium Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2093101/0001193125-26-224238-index.html","primary_entity_key":"0002093101","primary_entity_name":"Atrium Therapeutics, Inc."},"word_count":79,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\n99.1+\n  \n[Press Release, dated May 14, 2026](d82207dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n+\n\nFurnished herewith.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nATRIUM THERAPEUTICS, INC.\n\nDate: May 14, 2026\n \n\n \nBy:\n \n\n/s/ Kathleen Gallagher\n\n \n\n \n\n \n\nName: Kathleen Gallagher\n\nTitle: Chief Executive Officer"}